Advances in the treatment of MDS, multiple myeloma, and CLL.
Snively
Anne
A
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001897:Boronic Acids / Q000009:adverse effects / Q000627:therapeutic use; D000069286:Bortezomib; D016903:Drug Monitoring; D006801:Humans; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D009101:Multiple Myeloma / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D024802:Nurse's Role; D009859:Oncology Nursing; D011379:Prognosis; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use; D018570:Risk Assessment; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use